Celprogen Inc., a leader in the Stem Cell Research and Therapeutics industry for the development of stem cell technologies for regenerative medicine, today announced that they have developed STEMC5007, a synthetic molecule that is capable of stimulating and activating the internal stem cell population. 

This molecule can be administered by the following methods: intravenous, intra-peritoneal and intramuscular injections, and oral doses. The molecule STEMC5007 activates adult stem cell populations including progenitor stem cells, mesenchymal, skin, human hair follicle stem cells and adipose stem cells.

The present invention relates to increasing the stem cell population within the human organ systems without isolating and expanding the stem cells in a laboratory environment prior to administration of the stem cells back into the human body. 

The molecule STEMC5007 has been developed and optimized by Celprogen utilizing stem cell tissue culture technology. This technology will have a greater impact for patients that would require stem cell transplants; it works with the existing stem cell population in the individual's system. This molecule STEMC5007 is an interesting factor to be added to the regenerative medicine therapy and wound healing.